ArticleBMJ open2024

Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II-IIIA EGFR-mutated non-small cell lung cancer in China.

Lifeng Mu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.